<div id="readability-page-1"><p>Trexquant Investment LP decreased its holdings in shares of  Hims &amp; Hers Health, Inc. (NYSE:HIMS - Free Report) by 54.5% in the 1st quarter, according to its most recent 13F filing with the SEC. The fund owned 219,000 shares of the company's stock after selling 262,607 shares during the period. Trexquant Investment LP owned approximately 0.10% of Hims &amp; Hers Health worth $6,471,000 at the end of the most recent reporting period.</p><div><p><span></span><span>Get <strong>Hims &amp; Hers Health</strong> alerts:</span></p></div><ul><li>Ozempic Boom: Hims &amp; Eli Lilly Lead Healthcare Bets</li></ul><p>Several other institutional investors and hedge funds also recently made changes to their positions in HIMS. Farallon Capital Management LLC raised its position in shares of  Hims &amp; Hers Health by 64,338.5% during the 4th quarter. Farallon Capital Management LLC now owns 8,377,000 shares of the company's stock valued at $202,556,000 after acquiring an additional 8,364,000 shares during the last quarter.  Nuveen LLC bought a new stake in shares of  Hims &amp; Hers Health during the 1st quarter valued at $58,403,000.  Yong Rong HK Asset Management Ltd raised its position in shares of  Hims &amp; Hers Health by 41.2% during the 1st quarter. Yong Rong HK Asset Management Ltd now owns 2,400,000 shares of the company's stock valued at $70,920,000 after acquiring an additional 700,100 shares during the last quarter.  CloudAlpha Capital Management Limited Hong Kong bought a new stake in shares of  Hims &amp; Hers Health during the 1st quarter valued at $20,580,000.  Finally, Jump Financial LLC raised its position in shares of  Hims &amp; Hers Health by 633.2% during the 1st quarter. Jump Financial LLC now owns 725,445 shares of the company's stock valued at $21,437,000 after acquiring an additional 626,496 shares during the last quarter. Institutional investors own  63.52% of the company's stock. </p><h2>Wall Street Analyst Weigh In</h2><p>Several analysts have commented on the stock. Wall Street Zen cut shares of Hims &amp; Hers Health from a &#34;buy&#34; rating to a &#34;hold&#34; rating in a research report on Monday, July 28th. Zacks Research cut shares of Hims &amp; Hers Health from a &#34;strong-buy&#34; rating to a &#34;hold&#34; rating in a research report on Tuesday, August 19th. UBS Group  set a $30.00 price target on shares of Hims &amp; Hers Health in a report on Monday, June 23rd. Piper Sandler  reissued a &#34;neutral&#34; rating and issued a $39.00 price target (up previously from $35.00) on shares of Hims &amp; Hers Health in a report on Tuesday, May 6th. Finally, Needham &amp; Company LLC  reissued a &#34;hold&#34; rating on shares of Hims &amp; Hers Health in a report on Tuesday, August 5th. Two investment analysts have rated the stock with a Buy rating, eight have assigned  a Hold rating and three have issued  a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of &#34;Reduce&#34; and an average price target of $38.92.</p><ul><li>Insiders Trade Millions in NVIDIA-Linked Navitas, Hims, &amp; Shift4</li></ul><p><b>Check Out Our Latest Report on HIMS</b></p><h2>Hims &amp; Hers Health Price Performance</h2><p>Shares of HIMS stock opened at $42.36 on Friday. Hims &amp; Hers Health, Inc. has a 12-month low of $13.47 and a 12-month high of $72.98. The firm has a market capitalization of $9.57 billion, a price-to-earnings ratio of 52.95, a price-to-earnings-growth ratio of 2.86 and a beta of 2.08. The company has a quick ratio of 4.46, a current ratio of 4.98 and a debt-to-equity ratio of 1.72. The firm has a fifty day moving average of $49.98 and a 200-day moving average of $45.82. </p><ul><li>MarketBeat Week in Review – 08/04 - 08/08</li></ul><p>Hims &amp; Hers Health (NYSE:HIMS - Get Free Report) last announced its quarterly earnings results on Monday, August 4th. The company reported $0.17 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.18 by ($0.01). The firm had revenue of $544.83 million during the quarter, compared to analyst estimates of $550.06 million. Hims &amp; Hers Health had a net margin of 9.63% and a return on equity of 26.26%. Hims &amp; Hers Health's quarterly revenue was up 72.6% on a year-over-year basis. During the same period last year, the firm earned $0.06 EPS.  Hims &amp; Hers Health has set its Q3 2025 guidance at  EPS. FY 2025 guidance at  EPS. On average, equities research analysts forecast that  Hims &amp; Hers Health, Inc. will post 0.29 earnings per share for the current year. </p><h2>Insider Activity at Hims &amp; Hers Health</h2><p>In related news, insider Patrick Harrison Carroll sold 60,000 shares of the company's stock in a transaction on Wednesday, August 6th. The shares were sold at an average price of $53.58, for a total value of $3,214,800.00. Following the completion of the transaction, the insider directly owned 169,940 shares of the company's stock, valued at approximately $9,105,385.20. This represents a 26.09% decrease in their position. The sale was disclosed in a document filed with the Securities &amp; Exchange Commission, which is accessible through this link. Also, CEO Andrew Dudum sold 660,000 shares of the company's stock in a transaction on Thursday, August 7th. The stock was sold at an average price of $50.58, for a total transaction of $33,382,800.00. Following the completion of the transaction, the chief executive officer directly owned 2,214,769 shares of the company's stock, valued at approximately $112,023,016.02. The trade was a 22.96% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 1,395,428 shares of company stock valued at $71,753,898 in the last quarter. 13.71% of the stock is currently owned by company insiders. </p><h2>Hims &amp; Hers Health Profile</h2> (Free Report)<p>Hims &amp; Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA. </p><h2>Featured Articles</h2><ul><li>Five stocks we like better than Hims &amp; Hers Health</li><li>How to Effectively Use the MarketBeat Ratings Screener</li><li>DICKS’s Sporting Goods Stock Dropped After Earnings—Is It a Buy?</li><li>How to Know if a Stock Pays Dividends and When They Are Paid Out</li><li>Engines to AI: Cummins’ Surprising Growth Driver</li><li>Why is the Ex-Dividend Date Significant to Investors?</li><li>Smaller Industrials Names Seeing Surging Growth: Here's Why</li></ul><p><strong>Want to see what other hedge funds are holding HIMS?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hims &amp; Hers Health, Inc. (NYSE:HIMS - Free Report).</p><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUhJTVM?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUhJTVM"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Hims &amp; Hers Health Right Now?</h2><p>Before you consider Hims &amp; Hers Health, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Hims &amp; Hers Health wasn't on the list.</p><p>While Hims &amp; Hers Health currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

HIMS

<p>Trexquant Investment LP has reduced its stake in Hims & Hers Health, Inc. by 54.5%, selling 262,607 shares and now holding 219,000 shares. The fund's holdings are valued at approximately $6.47 million. Other institutional investors have also adjusted their positions, with significant increases from Farallon Capital Management and Jump Financial. Analysts have mixed ratings on Hims & Hers Health, with a consensus rating of 'Reduce' and an average price target of $38.92. The stock opened at $42.36, with a 12-month range of $13.47 to $72.98.</p>

Trexquant Investment LP Sells 262,607 Shares of Hims & Hers Health, Inc. $HIMS